The OAI classification implies that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved
He was appointed a Board member and the Chairman in 2012.
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
The product is expected to be available in a week’s time
It is the first approved generic and is eligible for 180 days of Competitive Generic Therapy exclusivity
Subscribe To Our Newsletter & Stay Updated
